undefined undefined
NaN.000
NaN.00%
TScan Therapeutics (NASDAQ:TCRX) underwent analysis by 4 analysts in the last q...
04-24 02:01
TScan Therapeutics (NASDAQ:TCRX) announces the pricing of its upsized underwritten public offering of 2,472,581 shares of its voting common stock at $7.13 per share, with an expected gross proceeds of...
04-17 15:37
TScan Therapeutics (TCRX) has provided an update. TScan Therapeutics, Inc. has ...
04-17 04:32
David Iben put it well when he said, 'Volatility is not a risk we care about. W...
02-20 19:10
Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $9 price target.
02-01 23:03
Investors who take an interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) should...
2023-12-23 20:23
TScan Therapeutics (NASDAQ:TCRX) reported its Q3 earnings results on Thursday, ...
2023-11-09 20:55
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Na...
2023-09-05 19:00